NCT07187531Phase 2Recruiting

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

Study sponsor: SAb Biotherapeutics, Inc. · SABS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-11Estimated
Enrollment · participants159Estimated
Source updated2026-10-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) Measure: Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT). After: Measure: Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) Measure: Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT) Measure: Part C: Area under the concentration-time curve (AUC) of C-peptide after a 2-hour mixed meal tolerance test (MMTT)..

Check registry source

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source